Sun Pharma and Philogen sign global licensing agreement for Fibromun EP News Bureau Oct 1, 2024 Agreement focuses on global commercialisation of anti-cancer immunotherapy
Sun Pharma, Philogen sign pact to commercialise specialty product, NIDLEGY in Europe, Australia and… EP News Bureau May 30, 2023 Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for…
